TABLE 5.
Mean (standard deviation) post hoc individual PK parameters from final population PK models by study drug and cohorta
| Drug and cohortb | CL (L/h) | CLR (L/h) | CLNR (L/h) | V1 (L) | Q (L/h) | V2 (L) |
|---|---|---|---|---|---|---|
| Ceftazidime | ||||||
| Cohort 1 | 8.70 (0.95) | 5.62 (0.89) | 3.07 (0.29) | 11.40 (2.34) | 7.08 (2.84) | 8.84 (2.72) |
| Cohort 2 | 8.94 (1.68) | 6.07 (0.97) | 2.87 (0.89) | 11.80 (2.24) | 4.93 (1.47) | 9.90 (2.31) |
| Cohort 5 | 7.70 (0.86) | 7.42 (0.85) | 0.28 (0.01) | 9.72 (1.93) | 6.40 (2.12) | 8.31 (2.28) |
| Cohort 6 | 8.19 (1.02) | 7.92 (1.02) | 0.27 (0.01) | 10.90 (2.17) | 7.50 (2.38) | 8.64 (2.40) |
| Avibactam | ||||||
| Cohort 1 | 14.60 (1.48) | 11.60 (1.15) | 2.97 (1.29) | 13.40 (3.08) | 8.09 (2.06) | 9.45 (2.42) |
| Cohort 2 | 14.80 (2.36) | 12.00 (1.35) | 2.80 (1.56) | 14.30 (2.97) | 5.29 (1.03) | 10.40 (2.10) |
| Cohort 5 | 12.30 (1.41) | 11.30 (1.16) | 0.97 (0.46) | 11.60 (2.72) | 7.70 (1.75) | 8.91 (2.04) |
| Cohort 6 | 13.20 (2.05) | 12.20 (1.87) | 0.96 (0.29) | 12.60 (2.80) | 7.96 (1.80) | 9.22 (2.16) |
| Aztreonam | ||||||
| Cohort 3 | 7.41 (0.99) | 4.70 (0.78) | 2.71 (0.28) | 3.59 (2.06) | 28.70 | 10.30 (0.82) |
| Cohort 4 | 6.70 (0.29) | 4.06 (0.28) | 2.64 (0.09) | 3.70 (0.92) | 28.70 | 9.90 (1.29) |
| Cohort 5 | 6.30 (0.69) | 4.67 (0.66) | 1.63 (0.13) | 3.76 (1.50) | 28.70 | 9.77 (1.25) |
| Cohort 6 | 6.42 (0.98) | 4.80 (0.93) | 1.62 (0.08) | 4.25 (1.93) | 28.70 | 9.75 (1.12) |
a
CL, total clearance; V1, volume of the central compartment; Q, intercompartmental clearance; V2, volume of the peripheral compartment; CLR, renal clearance; CLNR, nonrenal clearance.
b
Drug cohorts: CZA 2.5 g i.v. over 2 h every 8 h (cohort 1); CZA 2.5 g i.v. over 2 h × 1 and then 7.5 g/daily as a continuous infusion (CI) (cohort 2); ATM 2 g i.v. over 2 h every 6 h (cohort 3); ATM 2 g i.v. × 1 and then 8 g/daily as a CI (cohort 4); CZA 2.5 g i.v. over 2 h every 8 h with ATM 1.5 g i.v. over 2 h every 6 h (cohort 5; CZA 2.5 g i.v. over 2 h every 8 h with ATM 2 g i.v. over 2 h every 6 h (cohort 6).